Mayo Clinic and Mayo Clinic Alix School of Medicine, Phoenix, AZ.
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Am Soc Clin Oncol Educ Book. 2023 May;43:e389322. doi: 10.1200/EDBK_389322.
Advances in molecular profiling have led to improved understanding of glioma heterogeneity. Results have been used to inform diagnostic classification and targeted treatment strategies. Validation of these tests is necessary in the development of biomarkers that can aid in treatment decision, allowing for personalized medicine in neuro-oncologic diseases. Although not all populations have benefitted equally from awareness of and access to testing, opportunities arise regarding incorporating this testing into the standard of care for patients with glioma.
分子谱分析的进展使人们对神经胶质瘤异质性有了更深入的了解。研究结果被用于为诊断分类和靶向治疗策略提供信息。在开发有助于治疗决策的生物标志物时，这些测试的验证是必要的，这使得神经肿瘤学疾病能够实现个体化医疗。尽管并非所有人群都能平等地受益于对检测的认识和获得检测的机会，但在将这种检测纳入神经胶质瘤患者的标准治疗中，机会正在出现。
